Webinar recording: Optimizing CoGS in AAV and LVV Manufacturing

Scaling adeno-associated virus (AAV) and lentiviral vector (LVV) programs from process development to commercial manufacturing is one of the most demanding transitions in the viral vector space, and the margin for error narrows significantly at 1,000 L. This panel discussion brings together experts from large pharma, CDMOs, and biotech to tackle the practical, commercial, and scientific challenges that determine whether scale-up succeeds or stalls.
 

Watch panel recording to:

• Understand what a genuinely seamless R&D-to-GMP transition looks like in practice and how to identify and eliminate technical drift before it becomes a costly problem
  
  
• Hear why raw material specification decisions need to be made earlier than most teams expect, and what the real cost is of getting that call wrong
  
  
• Explore how the industry is thinking about scale-up validation from technical data to in-silico modelling and what it takes to demonstrate comparability to QA
  
  
• Debate whether platform processes are fit for purpose, as novel engineered capsids and pseudotyped lentiviruses with new envelope proteins push the boundaries of existing downstream workflows
  
  
• Discover what makes biotech-CDMO tech transfer succeed and what each party needs to bring to the table to avoid costly delays